TransMedics Group (NASDAQ:TMDX) Hits New 12-Month Low – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $58.27 and last traded at $58.71, with a volume of 304971 shares changing hands. The stock had previously closed at $61.02.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TMDX shares. Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

The firm has a 50-day simple moving average of $81.71 and a two-hundred day simple moving average of $126.05. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 62.39 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.12) EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 12.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,417 shares of company stock valued at $2,240,738. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Driehaus Capital Management LLC lifted its position in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. Hood River Capital Management LLC acquired a new stake in shares of TransMedics Group in the second quarter worth $18,854,000. Canada Pension Plan Investment Board bought a new position in TransMedics Group during the second quarter worth $16,086,000. Finally, Public Sector Pension Investment Board acquired a new position in TransMedics Group during the 3rd quarter valued at $11,079,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.